Skip to main content

News Release

Axolotl Biologix 

Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, was proud to participate in a day long symposium to discuss the future health of Arizona Tribes. The Chief Science Officer and two board members presented research into treating diabetes and combating opioid use at the 2019 Tribal Health Symposium, held September 20 at Talking Stick Resort in Scottsdale, Arizona.

Robert Kellar, Ph.D., Chief Science Officer, along with Dr. Kerry Zang, DPM, and Dr. Joel Rainwater, MD, presented their findings on how regenerative medicine can be used to treat chronic wounds caused by diabetes and reduce dependency on opioids. Rainwater, a board-certified interventional radiologist and Zang, founder of the Arizona Institute of Footcare Physicians and Chairman of Axolotl Biologix’s Medical Advisory Board, highlighted the presentation with case studies of patients who received treatment.

“Native Americans have a greater chance of having diabetes and patients living in rural Indian Communities may not have immediate access to medical care, so it was important for us to be able to educate physicians as well as the public about all the treatment options available,” said Robert Kellar, Ph.D., Chief Science Officer for Axolotl Biologix.

Scroll to Continue

Read More

Axolotl Biologix develops regenerative medicines such as liquid and membrane allografts to advance soft tissue repair, replacement, reconstruction and chronic wound care. The company’s product line was recently added to the Federal Supply Schedule (FSS) and is available through Indian Health Services.

“Innovative healthcare options like regenerative medicine starts a process that promotes healing through the rebuilding of tissues, and it is far more effective than a drug that temporarily masks pain,” said Dr. Kerry Zang.

“Regardless of whether they live in a rural area or near city centers, Native Americans deserve to have every option available to treat and overcome injuries and this symposium helped us educate members of the health care community as well as the general public,” said Dr. Joel Rainwater.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols.

For more information, visit